Mandate

VINGE ADVISES CARNEGIE IN CONNECTION WITH HANSA MEDICAL’S RIGHTS ISSUE AND BLOCK SALE OF FARSTORPS GÅRD’S SHARES

March 09, 2015

Hansa Medical has resolved to carry out a rights issue of MSEK 246 before deduction of issue related costs. The rights issue is fully guaranteed through subscription undertakings and underwriting. The proceeds from the issue will be used to finance the company’s future research and development activities. In connection herewith, the company also announced that Hansa Medical’s former majority shareholder, Farstorps Gård, has sold some of its holding to certain Swedish and international institutional owners.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes.. The company’s shares are admitted to trading on Nasdaq First North in Stockholm.

Vinge advised Carnegie which is the financial adviser in connection with the rights issue and sale. The team consists of Peter Bäärnhielm, Dain Nevonen and Sabina Börjesson.   

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025